6-(2-Aminopropyl)tetralin (6-APT), also sometimes called tetralinylaminopropane (TAP), is a drug of the amphetamine class which acts as a selective serotonin releasing agent (SSRA).[1] It has IC50 values of 121 nM, 6,436 nM, and 3,371 nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine, respectively.[1] Though it possesses an appreciable in vitro profile, in animal drug discrimination studies it was not found to substitute for MMAI or amphetamine and to only partially substitute for MBDB.[1] This parallels Alexander Shulgin's finding that EDMA (the 1,4-benzodioxine analogue of 6-APT) is limitedly active,[2] and appears to indicate that the pharmacokinetics of both EDMA and 6-APT may not be favorable.[1]

See also

References

  1. ^ a b c d Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE (November 1993). "Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine". Journal of Medicinal Chemistry. 36 (23): 3700–3706. doi:10.1021/jm00075a027. PMID 8246240.
  2. ^ Shulgin A, Shulgin A (13 May 2016). "EDMA · 3,4-Ethylenedioxy-N-methylamphetamine". Pihkal: A Chemical Love Story. Transform Press. ISBN 978-0-9630096-0-9.
Allikas: https://en.wikipedia.org/wiki/6-APT
No tags for this post.